SCHEMBL2652933

SCHEMBL2652933

CCOC(=O)c1cc(Cl)c2cc(OC)ccc2n1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSL P07711 1/20 0.61
CTSB P07858 1/20 0.61
ALDH1A1 P00352 8/20 0.53
KDM4E B2RXH2 8/20 0.53
HPGD P15428 8/20 0.53
SMN1; SMN2 Q16637 5/20 0.52
HSD17B10 Q99714 4/20 0.50
GAA P10253 2/20 0.50
MAPT P10636 6/20 0.49
NPC1 O15118 3/20 0.49
RAB9A P51151 3/20 0.49
LMNA P02545 3/20 0.48
PRNP P04156 1/20 0.48
POLB P06746 1/20 0.48
GABRA2 P47869 1/20 0.47
GABRB2 P47870 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
ELANE P08246 1/20 0.46
THRB P10828 1/20 0.46
MEN1 O00255 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2658663 0.86 CTSL (0.62) CTSLCTSBALDH1A1KDM4EHPGD
SCHEMBL9729781 0.85 ALDH1A1 (0.55) CTSLCTSBALDH1A1KDM4EHPGD
SCHEMBL27685906 0.84 KDM4E (0.55) ALDH1A1KDM4EHPGDHSD17B10LMNA
SCHEMBL20944487 0.83 MEN1 (0.60) ALDH1A1HPGDMAPTLMNAGABRA2
SCHEMBL27773370 0.82 KDM4E (0.50) ALDH1A1KDM4EHPGDSMN1; SMN2HSD17B10
SCHEMBL9319008 0.82 TNF (0.50) CTSLCTSBALDH1A1KDM4EHPGD
SCHEMBL163381 0.81 SMN1; SMN2 (0.53) ALDH1A1KDM4ESMN1; SMN2GAAMAPT
SCHEMBL6004248 0.81 GRM2 (0.54) ALDH1A1KDM4EHPGDHSD17B10MAPT
SCHEMBL3996643 0.80 SHMT2 (0.54) CTSLCTSBALDH1A1KDM4EHPGD
SCHEMBL16505799 0.80 HPGD (0.53) CTSLCTSBALDH1A1KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1773330-B1 SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE MERCK SHARP & DOHME (US) 2010-05-26 EP disclosed
US-7625938-B2 Substituted pyrazoles, compositions containing such compounds and methods of use MERCK & CO., INC. (US) 2009-12-01 US disclosed
EP-1773330-A4 SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE MERCK & CO INC (US) 2009-01-21 EP disclosed
US-20080108620-A1 Substituted Pyrazoles, Compositions Containing such Compounds and Methods of Use MERCK & CO., INC. (US) 2008-05-08 US disclosed
EP-1773330-A2 SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE Merck & Co., Inc. (US) 2007-04-18 EP disclosed
WO-2006014618-A2 SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE MERCK & CO., INC. (US) 2006-02-09 WO disclosed
EP-0478964-A1 Pyrazoloquinoline derivatives SHIONOGI SEIYAKU KABUSHIKI KAISHA (JP) 1992-04-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108620-A1 Substituted Pyrazoles, Compositions Containing such Compounds and Methods of Use GLP1R, GCGR, GPR119 CTSL 3400/4885CTSB 2174/4885ALDH1A1 3006/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.